PSA Screening: The Informed Decision Guide
Content last reviewed 2026-09-12 · Educational information — not medical advice
Quick answer
PSA screening reduces prostate-cancer mortality modestly while overdiagnosing indolent cancers meaningfully — hence shared decision-making replacing reflexive screening. Age-specific thresholds, free:total ratios, velocity tracking, and mpMRI now refine the pathway before any biopsy conversation.
The decision framework by age
- 40-45 baseline: high-risk men (Black patients, family history) start discussions/discussion-baselines
- 50-69 average-risk: shared decision-making zone — benefits/harms weighed personally
- 70+ : generally stop unless exceptional health/status argues continuation
Beyond the raw number
Free:total PSA ratio: cancer favors LOW free fractions (<25% raises suspicion at borderline totals). Velocity: rises >0.75/year warrant attention regardless of absolute values. mpMRI: revolutionized pre-biopsy triage — suspicious lesions get targeted, negatives defer confidently. PHI/4Kscore: blood-based refinements reducing unnecessary biopsies further.
What elevates PSA besides cancer
BPH (volume-driven), prostatitis (sometimes dramatically), recent ejaculation/cycling/exams (transient artifacts — 48hr abstinence pre-draw), catheterization, and finasteride users (halve readings mentally). Age-adjusted ranges acknowledge benign growth trajectories.
If elevated — the refined sequence
Repeat in 4-6 weeks controlling artifacts → persistent elevation: free:total ratio ± PHI/mpMRI → lesion-suspicion drives targeted biopsies (transperineal routes reducing infection) → Gleason grading determines active-surveillance-versus-treatment forks. Modern pathways spare most elevated-PSA men from biopsy entirely.
Order this test online
Direct-access laboratory testing — no appointment or doctor visit required. Results delivered as secure PDFs.
We may earn a commission when you order through partner links. Educational content only — never a substitute for professional medical advice.
Related guides
Frequently asked questions
USPSTF says don't screen — urologist disagrees. Truth?
Both hold fragments: harms real, deaths prevented real. Current consensus landed on INDIVIDUALIZED decisions ages 50-70 (45 if Black/high-risk) — you're entitled to want the test after hearing both sides.
Active surveillance — is ignoring cancer safe?
For Gleason-6 disease, surveillance protocols with scheduled re-evaluation show equivalent survival to immediate surgery with vastly fewer quality-of-life costs — medicine's best modern conservatism story.